References and Notes
1. Lauwerys RR, Hoet P. Industrial Chemical Exposure: Guidelines for Biological Monitoring. 2nd ed. Boca Raton, FL:Lewis Publishers, 1993.
2. Borjesson J, Mattsson S. Toxicology; in vivo x-ray fluorescence for the assessment of heavy metal concentrations in man. Appl Radiat Isot 46:571-576 (1995).
3. Hu H, Aro A, Rotnitzky A. Bone lead measured by X-ray fluorescence: epidemiologic methods. Environ Health Perspect 103(suppl 1):105-110 (1995).
4. Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect 106:1-8 (1998).
5. Todd AC, Chettle DR. In vivo X-ray fluorescence of lead in bone: review and current issues. Environ Health Perspect 102:172-177 (1994).
6. Emmerson BT, Thiele BR. Calcium versenate in the diagnosis of chronic lead nephropathy. Med J Aust 1:243-248 (1960).
7. Chisolm JJ. Mobilization of lead by calcium disodium edetate: a reappraisal. Am J Dis Child 141:1256-1257 (1987).
8. González-Ramírez D, Maiorino RM, Zuńiga-Charles MZ, et al. Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. II. Urinary mercury, prophyrins, and neurobehavioral changes of dental workers in Monterrey, Mexico. J Pharmacol Exp Ther 272:264-274 (1995).
9. Aposhian HV, Aposhian MM. Meso-2,3-dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Ann Rev Pharmacol Toxicol 30:279-306 (1990).
10. Graziano J. Conceptual and practical advances in the measurement and clinical management of lead toxicity. Neurotoxicology 14:219-223 (1993).
11. Liebelt EL, Shannon M, Graef JW. Efficacy of oral meso-2,3-dimercaptosuccinic acid therapy for low-level childhood plumbism. J Pediatr 124:313-317 (1994).
12. Guha Mazumder DN, Ghoshal UC, Saha J, Santra A, De BK, Chatterjee A, Dutta S, Angle CR, Centeno JA. Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water. J Toxicol Clin Toxicol 36:683-690 (1998).
13. Muckter H, Liebl B, Reichl FX, Hunder G, Walther U, Fichtl B. Are we ready to replace dimercaprol (BAL) as an arsenic antidote? Hum Exp Toxicol 16:460-465 (1997).
14. Slikkerveer A, Noach LA, Tytgat GN, Van der Voet GB, De Wolff FA. Comparison of enhanced elimination of bismuth in humans after treatment with meso-2,3-dimercaptosuccinic acid and D,L-2,3-dimercaptopropane-1-sulfonic acid. Analyst 123(1):91-92 (1998).
15. Aposhian HV, Maiorino RM, Rivera M, Bruce DC, Dart RC, Hurlbut KM, Levine DJ, Zheng W, Fernando Q, Carter D, et al. Human studies with the chelating agents, DMPS and DMSA. J Toxicol Clin Toxicol 30:505-528 (1992).
16. Lee B-K, Schwartz BS, Stewart W, Ahn K-D. Provocative chelation challenge with DMSA and EDTA: evidence for differential access to lead storage sites. Occup Environ Med 52:13-19 (1995).
17. Bluhm RE, Breyer JA, Bobbitt RG, Welch LW, Wood AJ, Bonfiglio JF, Sarzen C, Heath AJ, Branch RA. Elemental mercury vapour toxicity, treatment, and prognosis after acute, intensive exposure in chloralkali plant workers. Part I: History, neuropsychological findings and chelator effects. Hum Exp Toxicol 11:201-210 (1992).
18. Schwartz BS, Stewart WF, Todd AC, Links JM. Predictors of dimercaptosuccinic acid chelatable lead and tibial lead in former organolead manufacturing workers. Occup Environ Med 56:22-29 (1999).
19. Gerhardsson L, Borjesson J, Mattsson S, Schutz A, Skerfving S. Chelated lead in relation to lead in bone and ALAD genotype. Environ Res 80(4):389-398 (1999).
20. Buchet JP, Lauwerys RR. Influence of 2,3-dimercaptopropane-1-sulfonate and dimercaptosuccinic acid on the mobilization of mercury from tissues of rats pretreated with mercuric chloride, phenylmercury acetate or mercury vapors. Toxicology 54(3):323-333 (1989).
21. Gale GR, Smith AB, Jones MM, Singh PK. Meso-2,3-dimercaptosuccinic acid monoalkyl esters: effects on mercury levels in mice. Toxicology 81(1):49-56 (1993).
22. Liang YY, Zhang JS, Tao ZQ, Yan XM, Xu XH, Chen ZJ. Effect of dimercaptosuccinic acid per os on distribution and excretion of 210Pb and 203Hg in mice [in Chinese]. Chung Kuo Yao Li Hsueh Pao 15(4):379-82 (1994).
23. Kostial K, Restek-Samarzija N, Blanusa M, Piasek M, Jones MM, Singh PK. Combined oral treatment with racemic and meso-2,3-dimercaptosuccinic acid for removal of mercury in rats. Pharmacol Toxicol 81(5):242-244 (1997).
24. Kostial K, Restek-Samarzija N, Blanusa M, Piasek M, Prester L, Jones MM, Singh PK. Racemic-2,3-dimercaptosuccinic acid for inorganic mercury mobilization in rats. J Appl Toxicol 17:71-74 (1997).
25. de la Torre A, Belles M, Llobet JM, Mayayo E, Domingo JL. Comparison of the effectiveness of 2,3-dimercaptopropanol (BAL) and meso-2,3-dimercaptosuccinic acid (DMSA) as protective agents against mercuric chloride-induced nephrotoxicity in rats. Biol Trace Elem Res 63(1):1-10 (1998).
26. Roels HA, Boeckx M, Ceulemans E, Lauwerys RR. Urinary excretion of mercury after occupational exposure to mercury vapor and influence of the chelating agent meso-2,3-dimercaptosuccinic acid (DMSA). Br J Ind Med 48:247-253 (1991).
27. Englund GS, Dahlqvist R, Lindelof B, Soderman E, Jonzon B, Vesterberg O, Larsson KS. DMSA administration to patients with alleged mercury-poisoning from dental amalgams: a placebo-controlled study. J Dent Res 73:620-628 (1994).
28. Houeto P, Sandouk P, Baud FJ, Levillain P. Elemental mercury-vapor toxicity: treatment and levels in plasma and urine. Hum Exp Toxicol 13:848-852 (1994).
29. Grandjean P, Guldager B, Larsen IB, Jorgensen PJ, Holmstrup P. Placebo response in environmental disease. Chelation therapy of patients with symptoms attributed to amalgam fillings. J Occup Environ Med 39:707-714 (1997).
30. Nierenberg DW, Nordgren RE, Chang MB, Siegler RW, Blayney MB, Hochberg F, Toribara TY, Cernichiari E, Clarkson T. Delayed cerebellar disease and death after accidental exposure to dimethylmercury. N Engl J Med 338:1672-1676 (1998).
31. Forman J, Moline J, Cernichiari E, Sayegh S, Torres JC, Landrigan MM, Hudson J, Adel HN, Landrigan PJ. A cluster of pediatric metallic mercury exposure cases treated with meso-2,3-dimercaptosuccinic acid (DMSA). Environ Health Perspect 108:575-577 (2000).
32. Hursh JB, Cherian MG, Clarkson TW, Vostal JJ, Mallie RV. Clearance of mercury (Hg-197, Hg-203) vapor inhaled by human subjects. Arch Environ Health 31(6):302-309 (1976).
33. Clarkson TW. Mercury. J Am Coll Toxicol 8:1291-1296 (1989).
34. Sallsten G, Barregard L, Schutz A. Decrease in mercury concentration in blood after long-term exposure: a kinetic study of chloralkali workers. Br J Ind Med 50:814-821 (1993).
35. Sallsten G, Barregard L, Schutz A. Clearance half-life of mercury in urine after the cessation of long-term occupational exposure: influence of a chelating agent (DMPS) on excretion of mercury in urine. Occup Environ Med 51:337-342 (1994).
36. Takahata N, Hayashi H, Watanabe B, Anso T. Accumulation of mercury in the brains of two autopsy cases with chronic inorganic mercury poisoning. Folia Psychiatr Neurol Jpn 24:59-69 (1970).
37. Zalups RK. Influence of 2,3-dimercaptopropane-1-sulfonate (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the renal disposition of mercury in normal and uninephrectomized rats exposed to inorganic mercury. J Pharmacol Exp Ther 267(2):791-800 (1993).
38. Mottet NK, Body RL. Mercury burden of human autopsy organs and tissues. Arch Environ Health 29:18-24 (1974).
39. Florentine MJ, Sanfilippo DJ. Elemental mercury poisoning. Clin Pharm 10:213-221 (1991).
40. Schiele R, Schaller KH, Weltle D. Mobilization of mercury reserves in the organism by means of DMPS (Dimaval). Occup Med Soc Med Prev Med 24:249-251 (1989).
41. Gerhard I, Waldbrenner P, Thruo H, Runnebaum B. Diagnosis of heavy metal loading by the oral DMPS and chewing-gum tests. Klin Lab 38:404-411 (1992).
42. Frumkin H, Letz R, Williams PL, Gerr F, Pierce P, Sanders A, Elon L, Manning CC, Woods JS, Hertzberg VS, et al. Health effects of long-term mercury exposure among chloralkali plant workers. Am J Ind Med 39:1-18 (2001).
43. Williams PL, Frumkin H, Pierce ML, Manning CC, Elon L, Sanders AG. Reconstruction of occupational mercury exposures at a chloralkali plant. Occup Environ Med (in press).
44. McGill CM, Ladd AC, Jacobs MB, Goldwater LJ. Mercury exposure in a chlorine plant. J Occup Med 6:335-337 (1964).
45. Smith RG, Vorwald AJ, Patil LS, Mooney TF. Effects of exposure to mercury in the manufacture of chlorine. Am Ind Hyg Assoc J 31:687-700 (1970).
46. Bunn WB, McGill CM, Barber TE, Cromer JW, Goldwater LJ. Mercury exposure in chloralkali plants. Am Ind Hyg Assoc J 45:249-254 (1986).
47. Littlejohn D, Fell GS, Ottoway JM. Modified determination of total and inorganic mercury in urine by cold vapor atomic absorption spectrometry. Clin Chem 22:1719-1723 (1976).
48. Greenwood MR, Dhahir P, Clarkston TW, Farrant JP, Chartrand A, Khayat A. Epidemiological experience wtih Magos' reagent in the determination of different forms of mercury in biological samples by flameless atomic absorption. J Anal Toxicol 1:265-269 (1977).
49. Aposhian HV, Bruce DC, Alter W, Dart RC, Hurlbut KM, Aposhian MM. Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid: correlation with the dental amalgam score. FASEB J 6:2472-2476 (1992).
50. Lorscheider FL, Vimy MJ, Summers AO. Mercury exposure from "silver" tooth fillings: emerging evidence questions a traditional dental paradigm. FASEB J 9:504-508 (1995).
51. Bergdahl IA, Schütz A, Ahlqwist M, Bengtsson C, Lapidus L, Lissner L, Hultén B. Methylmercury and inorganic mercury in serum--correlation to fish consumption and dental amalgam in a cohort of women born in 1922. Environ Res 77:20-24 (1998).
52. Halbach S, Kremers L, Willruth H, Mehl A, Welzl G, Wack FX, Hickel R, Greim H. Systemic transfer of mercury from amalgam fillings before and after cessation of emission. Environ Res 77:115-123 (1998).
Last Updated: January 25, 2001